Vertaling van "billion as well as femara and sandostatin " (Nederlands → Frans) :

Other products achieving annual net sales of more than USD 1 billion were Zometa (USD 1.4 billion) as well as Femara and Sandostatin (each USD 1.1 billion).
Trois autres produits – Zometa (USD 1,4 milliard), Femara et Sandostatine (USD 1,1 milliard chacun) – ont affiché un chiffre d’affaires net supérieur à USD 1 milliard.

Oncology (USD 9.0 billion, +14% lc) remained the largest franchise and ranks No. 2 in the global oncology segment, led by sustained growth of Gleevec/Glivec (USD 3.9 billion, +12% lc) and three additional products – Zometa, Femara and Sandostatin – that each achieved more than USD 1 billion of sales.
Oncologie (USD 9,0 milliards, +14% en m. l) est restée le domaine thérapeutique stratégique le plus important, classé n° 2 du segment oncologie à l’échelle mondiale. Ce domaine a été emmené par la croissance soutenue de Glivec/Gleevec (USD 3,9 milliards, +12% en m. l) et par trois autres produits – Zometa, Femara et Sandostatine – qui ont réalisé chacun plus d’USD 1 milliard de ventes.

Oncology (USD 2.5 billion, +9% cc), the largest franchise, was led by sustained growth of Gleevec/Glivec (USD 1.0 billion, +6% cc), Femara (USD 343 million, +6% cc), and Sandostatin (USD 318 million, +8% cc).
Oncologie (USD 2,5 milliards, +9% tcc), le plus important d’entre eux, a été tirée vers le haut par la croissance soutenue de Glivec/Gleevec (USD 1,0 milliard, +6% tcc), Femara (USD 343 millions, +6% tcc) et Sandostatine (USD 318 millions, +8% tcc).

Oncology (USD 2.5 billion, +11% cc), the largest franchise, was led by sustained growth of Gleevec/Glivec (USD 1.1 billion, +8% cc), Femara (USD 338 million, +10% cc), and Sandostatin (USD 312 million, +11% cc), and important contributions from the recently launched products Exjade (USD 192 million, +11% cc), Tasigna (USD 89 million, +73% cc) and Afinitor (USD 55 million).
Oncologie (USD 2,5 milliards, +11% tcc), le plus grand domaine thérapeutique stratégique, a bénéficié de la croissance soutenue de Glivec/Gleevec (USD 1,1 milliard, +8% tcc), Femara (USD 338 millions, +10% tcc), et Sandostatine (USD 312 millions, +11% tcc), ainsi que d’importantes contributions fournies par Exjade (USD 192 millions, +11% tcc), Tasigna (USD 89 millions, +73% tcc) et Afinitor (USD 55 millions) lancés récemment.